North America Cancer Radiation Therapy Market Outlook (2021–2031)

The North America cancer radiation therapy market size is expected to reach US$ 55,989.1 million by 2031 from US$ 24,028.1 million in 2024. The market is estimated to record a CAGR of 13.0% from 2025 to 2031.

Executive Summary and North America Cancer Radiation Therapy Market Analysis:

The North America cancer radiation therapy market is highly advanced, supported by well-established healthcare infrastructure, widespread adoption of innovative technologies, and strong emphasis on precision oncology. Rising prevalence of breast, prostate, and lung cancers has fueled demand for sophisticated treatment modalities, including intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), proton therapy, and image-guided radiotherapy (IGRT). The region benefits from a dense network of specialized cancer centers and academic hospitals that integrate cutting-edge imaging, treatment planning software, and multidisciplinary oncology services. Collaboration between healthcare institutions, research organizations, and medical technology providers ensures rapid adoption of emerging radiotherapy innovations and continuous improvement of clinical protocols.

Opportunities for growth in North America stem from the integration of AI-assisted treatment planning, adaptive radiotherapy, and cloud-enabled workflow systems that improve precision, patient throughput, and accessibility in both urban and semi-urban centers. Ongoing government initiatives, insurance coverage expansion, and public-private partnerships are driving investment in new cancer centers and high-technology equipment. Additionally, regional focus on clinical trials, outcome tracking, and precision medicine supports the adoption of personalized radiation therapy strategies, positioning North America for sustained leadership in advanced oncology care and innovation in radiation therapy delivery.

North America Cancer Radiation Therapy Market - Strategic Insights:

North America Cancer Radiation Therapy Market Segmentation Analysis:

Key segments that contributed to the derivation of the North America cancer radiation therapy market analysis are type, cancer type, and end user.

• By type, the cancer radiation therapy market is segmented into external beam radiation therapy and internal beam radiation therapy. The external beam radiation therapy segment dominated the market in 2024.
• Based on cancer type, the cancer radiation therapy market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, head & neck cancer, cervical cancer, and others. The lung cancer segment dominated the market in 2024.
• In terms of end user, the cancer radiation therapy market is segmented into hospitals, specialty clinics, ambulatory and radiotherapy centers, and academic and research institutes. The hospitals segment dominated the market in 2024.

North America Cancer Radiation Therapy Market Drivers and Opportunities:

Increasing Burden of Cancer

Cancer prevalence continues to rise across North America, driven by aging populations, lifestyle factors, and environmental exposures. The US reports high burdens of breast, lung, and colorectal cancers, while Canada faces increasing prostate and skin cancer cases linked to demographic and behavioral trends. Obesity and smoking remain significant contributors, particularly in rural and underserved communities, while longer life expectancy ensures that age‑related cancers are more frequently diagnosed. This growing disease burden underscores the critical role of radiation therapy in comprehensive cancer care.

Screening programs and advanced diagnostics are channeling more patients into radiotherapy pathways. The US benefits from widespread mammography and colonoscopy programs, while Canada's organized cervical and colorectal screening initiatives are improving early detection. External beam radiation therapy is the dominant modality across major cancer centers in New York, Toronto, and Houston, while brachytherapy is widely used for prostate and gynecologic cancers. The increasing patient flow is placing pressure on hospitals to expand linear accelerator fleets and adopt more efficient treatment schedules.

Healthcare systems are investing heavily in oncology infrastructure to meet rising demand. Federal funding in the US supports cancer research and technology upgrades, while provincial programs in Canada prioritize equitable access to radiotherapy across urban and rural regions. As awareness campaigns and vaccination programs (HPV, hepatitis B) expand, more patients are diagnosed at treatable stages, reinforcing cancer prevalence as a sustained driver of the North American radiation therapy market.

Growing Trend Toward Patient-Centered Treatments

Personalized medicine is reshaping cancer care across North America, with precision diagnostics, genomics, and advanced imaging driving individualized radiotherapy approaches. US cancer centers integrate molecular profiling into treatment planning, tailoring radiation doses to tumor biology and radio sensitivity. Canadian hospitals increasingly use MRI and PET/CT for adaptive contouring, enabling clinicians to refine dose delivery and minimize toxicity. This shift toward personalization is improving outcomes and patient satisfaction.

Technology adoption is broadening the personalization toolkit. Intensity‑modulated and image‑guided radiotherapy are standard in leading centers, while stereotactic body radiotherapy is widely used for oligometastatic disease and early‑stage lung cancer. Proton therapy facilities in the US and Canada provide organ‑sparing options for pediatric, head‑and‑neck, and thoracic tumors, while AI‑assisted planning platforms are emerging to optimize dose distributions and reduce inter‑clinician variability. These innovations enable customized treatment pathways.

Policy and reimbursement frameworks are reinforcing the move toward individualized care. Medicare and private insurers in the US increasingly cover advanced radiotherapy techniques, while Canadian provincial health systems fund precision platforms to ensure equitable access. Patients are seeking shorter, hypofractionated schedules with fewer side effects, and providers are responding with adaptive workflows and integrated care models. This rising demand for personalized medicine creates a strong opportunity for vendors, service providers, and healthcare systems to deliver advanced radiation therapy solutions tailored to North America's diverse patient population.

North America Cancer Radiation Therapy Market Size and Share Analysis:

The North America cancer radiation therapy market demonstrates steady growth, with size and share analysis highlighting evolving trends and competitive dynamics among key players. The report further examines subsegments categorized within type, cancer type, and end user, offering insights into their contribution to overall market performance.

By type, the external beam radiation therapy subsegment dominated the market in 2024. Due to its widespread availability, precision targeting, noninvasive nature, and effectiveness in treating diverse cancers, it is the preferred choice across global oncology practices.

Based on cancer type, the lung cancer subsegment dominated the market in 2024. Due to its high incidence, strong link with smoking and pollution, late‑stage diagnoses, and reliance on advanced radiation techniques, it is the most treated cancer type globally.

In terms of end user, the hospitals subsegment dominated the market in 2024. Hospitals dominated the market since they provide comprehensive cancer care, advanced radiation infrastructure, skilled oncologists, and integrated treatment pathways, making them the primary setting for delivering radiation therapy services.

North America Cancer Radiation Therapy Market Report Highlights:

North America Cancer Radiation Therapy Market Report Coverage and Deliverables:

The "North America Cancer Radiation Therapy Market Size and Forecast (2021 - 2031)" report provides a detailed analysis of the market covering below areas:

• North America Cancer Radiation Therapy market size and forecast at regional and country levels for market segments covered under the scope
• North America Cancer Radiation Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• North America Cancer Radiation Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the North America Cancer Radiation Therapy market
• Detailed company profiles, including SWOT analysis

North America Cancer Radiation Therapy Market Geographic Insights:

The geographical scope of the North America Cancer Radiation Therapy market report is divided into: The US, Canada, and Mexico. The US held the largest share in 2024.

The US dominates the North America cancer radiation therapy market due to its extensive oncology infrastructure, early adoption of advanced technologies, and strong clinical expertise. Leading cancer centers in cities such as New York, Boston, Houston, and Los Angeles provide comprehensive radiotherapy services, including IMRT, IGRT, SBRT, proton therapy, and brachytherapy. These centers integrate sophisticated imaging, treatment planning, and patient management systems, enabling high-precision care and multidisciplinary treatment coordination. US leadership is reinforced by continuous investment in research, technology development, and clinical training programs that keep the workforce at the forefront of emerging radiation therapy techniques. Academic and private institutions collaborate on clinical trials, protocol standardization, and innovation, ensuring rapid deployment of next-generation therapies. Combined with robust healthcare funding, a high density of advanced cancer centers, and widespread access to specialized clinicians, the US maintains its position as the dominant force driving radiation therapy adoption and innovation in North America.

North America Cancer Radiation Therapy Market Research Report Guidance:

• The report includes qualitative and quantitative data in the North America cancer radiation therapy market across type, cancer type, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the North America Cancer Radiation Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the North America Cancer Radiation Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the North America Cancer Radiation Therapy market scenario, in terms of historical market revenues, and forecast till the year 2031.
• Chapters 7 to 10 cover North America Cancer Radiation Therapy market segments by type, cancer type, end user, and geography across the US, Canada, and Mexico. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.

North America Cancer Radiation Therapy Market News and Key Development:

The North America Cancer Radiation Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America cancer radiation therapy market are:

• In September 2025, Accuray Incorporated announced the launch of Accuray Stellar all‑in‑one radiotherapy solution—a versatile system designed to deliver a full range of radiation treatment modalities (from IMRT to SBRT and adaptive radiotherapy) in a streamlined workflow—aimed at expanding advanced radiotherapy capabilities for cancer centers across North America.
• In September 2025, Mevion Medical Systems announced that it showcased the newly FDA‑cleared MEVION S250‑FIT proton therapy system at ASTRO 2025—a novel proton therapy solution that can fit into existing linear accelerator (LINAC) vaults— facilitating broader clinical access and adoption across US and Canadian cancer treatment facilities.

Key Sources Referred:

• The World Bank
• World Health Organization (WHO)
• Center for Disease Control and Prevention (CDC)
• Union for International Cancer Control (UICC)
• International Agency for Research on Cancer (IARC)
• American Society for Radiation Oncology (ASTRO)
• European Society for Radiotherapy & Oncology (ESTRO)
• Asia-Oceania Federation of Organizations for Radiological Technology (AOFRT)
• Company Websites
• Company Annual Reports
• Company Investor Presentations